- Home
- POET vs ELDN Comparison
POET vs ELDN Comparison
Compare POET & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- POET
- ELDN
- Stock Information
- Founded
- POET 1972
- ELDN 2004
- Country
- POET Canada
- ELDN United States
- Employees
- POET N/A
- ELDN N/A
- Industry
- POET Semiconductors
- ELDN Biotechnology: Pharmaceutical Preparations
- Sector
- POET Technology
- ELDN Health Care
- Exchange
- POET Nasdaq
- ELDN Nasdaq
- Market Cap
- POET 206.6M
- ELDN 104.0M
- IPO Year
- POET N/A
- ELDN N/A
- Fundamental
- Price
- POET $2.76
- ELDN $2.54
- Analyst Decision
- POET
- ELDN Strong Buy
- Analyst Count
- POET 0
- ELDN 3
- Target Price
- POET N/A
- ELDN $11.67
- AVG Volume (30 Days)
- POET 918.8K
- ELDN 48.7K
- Earning Date
- POET 08-14-2024
- ELDN 08-18-2024
- Dividend Yield
- POET N/A
- ELDN N/A
- EPS Growth
- POET N/A
- ELDN N/A
- EPS
- POET N/A
- ELDN N/A
- Revenue
- POET $116,261.00
- ELDN N/A
- Revenue This Year
- POET $65.12
- ELDN N/A
- Revenue Next Year
- POET $1,736.87
- ELDN N/A
- P/E Ratio
- POET N/A
- ELDN N/A
- Revenue Growth
- POET N/A
- ELDN N/A
- 52 Week Low
- POET $0.72
- ELDN $1.07
- 52 Week High
- POET $4.05
- ELDN $3.35
- Technical
- Relative Strength Index (RSI)
- POET 45.01
- ELDN 35.62
- Support Level
- POET $2.82
- ELDN $2.71
- Resistance Level
- POET $2.99
- ELDN $2.92
- Average True Range (ATR)
- POET 0.28
- ELDN 0.17
- MACD
- POET -0.03
- ELDN -0.04
- Stochastic Oscillator
- POET 15.08
- ELDN 20.69
About POET POET Technologies Inc.
POET Technologies Inc offers integration solutions based on the POET Optical Interposer, a novel platform for the seamless integration of electronic and photonic devices into a single module using wafer-level manufacturing techniques and packaging methods. The company operates in a single segment of design, manufacture, and sale of semiconductor products and services for commercial applications. The products of the company are POET Starlight, POET Lightbar, POET Infinity, POET One, and others. Its products have applications in Data Centers, Telecommunications, the Internet of Things & Industrial Sensing, Automotive LIDAR, and On-Board Optics. Its geographical segments are Asia, the United States, and Canada.
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company's compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.